Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
BioNTech, Genentech cancel ph. 2 test of personalized cancer vax
An independent safety board recommended the trial be terminated early after more deaths were observed in patients given the customized mRNA vaccine.
Darren Incorvaia
Aug 28, 2026 1:50pm
Double shot of Vistagen’s anxiety nasal spray misses in ph. 2
Aug 6, 2026 10:32am
Altimmune GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 win
Jul 28, 2026 10:27am
MapLight shares sink on mixed ph. 2 schizophrenia readout
Jul 27, 2026 11:37am
Biogen defends anti-tau drug after stock slide
Jul 14, 2026 2:00pm
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy
Jul 1, 2026 2:35pm
